Sunday, June 21, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 791 of 1,261
  1. US 8841288

    Quinolin-4 (1H)-one derivatives as inhibitors of phosphatidylinositol 3-kinases

    UNIVERSITÀ DEGLI STUDI DEL PIEMONTE ORIENTALE “AMEDEO AVOGADRO” · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted
  2. US 8841295

    5-lipoxygenase-activating protein (FLAP) inhibitors

    Panmira Pharmaceuticals, LLC · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted
  3. US 8841305

    Activators of the human pyruvate kinase M2 receptor

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted
  4. US 8841337

    Compounds useful as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted
  5. US 8841449

    Compounds useful as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted
  6. US 8841323

    1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors

    Addex Pharma, S.A. · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted
  7. US 8841450

    Compounds useful as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted
  8. US 8841258

    Methods to accelerate tissue and wound healing rates and reduce swelling and scar formation

    The Regents of the University of California · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted
  9. US 8841483

    Compositions useful as inhibitors of voltage-gated sodium channels

    Vertex Pharmaceuticals Incorporated · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted
  10. US 8841273

    Methods and compositions for anti-EGFR treatment

    The Board of Regents of the University of Texas System · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted
  11. US 8841257

    Inhibitors of STAT3 and uses thereof

    The Board of Regents of the University of Texas System · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted
  12. US 8841266

    Pharmaceutical composition and method for regulating abnormal cellular proliferation

    The United States of America as Represented by The Secretary of the Department of Health and Human Services National Institutes of Health Office of Technology Transfer · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted
  13. US 8840926

    Sialic acid analogs

    Ultragenyx Pharmaceutical Inc. · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted
  14. US 8840905

    Use of neurotoxin therapy for treatment of urologic and related disorders

    The Regents of the University of Colorado · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted
  15. US 8840886

    Method of treating cancer with DLL4 antagonist and chemotherapeutic agent

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted
  16. US 8840894

    Antibodies to human GDF8

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted
  17. US 8840868

    Non-invasive detection of complement-mediated inflammation using CR2-targeted nanoparticles

    The Regents of the University of Colorado, a Body Corporate · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted
  18. US 8840978

    Identification device having antimicrobial properties

    Precision Dynamics Corporation · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted
  19. US 8841120

    Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity

    Takeda Vaccines, Inc. · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted
  20. US 8841282

    Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels

    Vertex Pharmaceuticals Incorporated · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted
  21. US 8840928

    Tamper-resistant pharmaceutical compositions of opioids and other drugs

    Collegium Pharmaceutical, Inc. · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted
  22. US 8841260

    Methods and compositions for treating Huntington's Disease

    Sangamo Biosciences, Inc. · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted
  23. US 2014271721

    PEANUT FORMULATIONS AND USES THEREOF

    ALLERGEN RES CORP [US] · Granted Sep 18, 2014 · Expires Sep 13, 2034

    granted
  24. US 2014271836

    MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION

    ALLERGEN RES CORP [US] · Granted Sep 18, 2014 · Expires Sep 13, 2034

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.